secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138253
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation
--------------------------------------------------------------------------------

- Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.
- FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.
- Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.
- Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.
- Cash $124M; expects to fund operations into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/d833929d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer